intelmarketp

 According to a new report from Intel Market Research , the global Interferons (IFNs) market was valued at USD 4.64 billion in 2024 and is projected to reach USD 8.18 billion by 2034 , growing at a CAGR of 8.7% during the forecast period (2025–2034). This expansion is driven by increasing applications in chronic disease management, particularly for hepatitis, multiple sclerosis, and certain cancers, coupled with continuous advancements in biotechnology. 📥 Download FREE Sample Report: Interferons (IFNs) Market - View in Detailed Research Report Understanding Interferons (IFNs) Interferons represent a critical class of signaling proteins naturally produced by host cells in response to viral infections, tumors, and other pathogenic threats. These proteins - categorized into Type I (IFN-α/β), Type II (IFN-γ), and Type III (IFN-λ) - function as the immune system's first responders, activating cellular defenses and modulating immune responses. Their therapeutic application has revo...

 According to new market analysis from Intel Market Research , the global Filgrastim market was valued at USD 4.8 billion in 2025 and is projected to reach USD 7.9 billion by 2034 , growing at a steady CAGR of 5.3% during the forecast period (2025-2034). This growth trajectory reflects the critical role Filgrastim plays in modern oncology care and its expanding use across global healthcare systems. 📥  Download Sample Report:   Filgrastim Market - View in Detailed Research Report What is Filgrastim? Filgrastim , marketed under brand names including Neupogen, Granix, and Zarxio, is a recombinant granulocyte colony-stimulating factor (G-CSF) that stimulates bone marrow to produce neutrophils. As a biologic medication, it has become essential for: Preventing infection in chemotherapy patients suffering from neutropenia Treating severe chronic neutropenia (SCN) Supporting hematopoietic stem cell transplantation protocols The drug's ability to significantly reduce the incid...

 According to a new report from Intel Market Research , the global Placenta Extract market was valued at USD 320 million in 2025 and is projected to reach USD 520 million by 2034 , growing at a CAGR of 5.1% during the forecast period (2026–2034). This growth is driven by increasing demand for anti-aging skincare products, rising therapeutic applications, and advancements in bioprocessing technologies. 📥  Download FREE Sample Report:   Placenta Extract Market - View in Detailed Research Report What is Placenta Extract? Placenta extract is a bioactive substance derived from human or animal placental tissue, containing growth factors, proteins, hyaluronic acid, collagen, and essential nutrients. It's widely used in cosmetics, pharmaceuticals, and nutraceuticals due to its regenerative properties that promote cell renewal and tissue repair. The extract's ability to stimulate collagen production and enhance skin elasticity has made it particularly valuable in anti-aging ...

 According to a new report from Intel Market Research , the global Diphtheria Vaccines market was valued at USD 3.42 billion in 2025 and is projected to reach USD 5.91 billion by 2034 , growing at a steady CAGR of 6.1% during the forecast period (2026-2034). This sustained growth reflects the critical role of vaccination programs in global public health initiatives and the pharmaceutical industry's continued investment in immunization technologies. 📥  Download Sample Report:   Diphtheria Vaccines Market - View in Detailed Research Report What are Diphtheria Vaccines? Diphtheria vaccines are essential biological preparations that provide immunity against Corynebacterium diphtheriae , the bacterium causing diphtheria. These vaccines contain diphtheria toxoid - an inactivated form of the bacterial toxin that safely stimulates antibody production without causing disease. Modern formulations typically combine protection against multiple diseases, with key variants includi...

 According to a new report from Intel Market Research , the global Elotuzumab market was valued at USD 1.45 billion in 2025 and is projected to reach USD 2.85 billion by 2034 , growing at a CAGR of 7.6% during the forecast period (2026–2034). This growth is driven by increasing prevalence of multiple myeloma, advancements in immunotherapy, and expanding treatment applications. 📥  Download FREE Sample Report:   Elotuzumab Market - View in Detailed Research Report What is Elotuzumab? Elotuzumab is a monoclonal antibody immunotherapy targeting the SLAMF7 protein on multiple myeloma cells, activating the immune system's natural killer cells to destroy cancer cells. Marketed under the brand name Empliciti® , it's typically administered in combination with lenalidomide and dexamethasone, demonstrating significant improvements in progression-free survival for patients with relapsed or refractory multiple myeloma. This report provides comprehensive analysis of the global Elo...

 According to a new report from Intel Market Research , the global TACE Embolic Microspheres market was valued at USD 1.44 billion in 2025 and is projected to reach USD 2.63 billion by 2034 , growing at a robust CAGR of 9.2% during the forecast period (2025–2034). This growth is driven by rising liver cancer prevalence, technological advancements in embolization materials, and increasing adoption of minimally invasive procedures. 📥  Download FREE Sample Report:   TACE Embolic Microspheres Market - View in Detailed Research Report What are TACE Embolic Microspheres? TACE Embolic Microspheres are specialized medical devices used in transcatheter arterial chemoembolization (TACE) therapy, primarily for treating liver cancer. These microspheres function by delivering chemotherapy drugs directly to tumors while simultaneously blocking their blood supply, starving cancerous cells of oxygen and nutrients. Available in drug-loaded or non-drug-loaded variants, they enhance tr...